3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Neoplasms
3
Vascular Diseases
2
Heart Diseases
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Neoplasms, Second Primary
1
Metabolic Diseases
1
Heart Failure
1
Drug-Related Side Effects and Adverse Reactions
1
Colorectal Cancer Metastatic
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Cancer Therapy-related Cardiovascular Toxicity
1
Breast Neoplasms
1
Advanced Ovarian Cancer
1
Interventions
Amifostine
4
Cisplatin
3
Voriconazole
2
Radiotherapy
2
Paclitaxel
2
Methotrexate
2
Drug Therapy
2
selinexor
1
sargramostim
1
pazopanib
1
lometrexol
1
icotinib
1
glucarpidase
1
camrelizumab
1
bismuth tripotassium dicitrate
1
apatinib
1
Telbivudine
1
Surgical Procedures, Operative
1
Pregabalin
1
Pharmaceutical Preparations
1
Ofloxacin
1
Nivolumab
1
Metronidazole
1
Levofloxacin
1
Imatinib Mesylate
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gefitinib
1
Folic Acid
1
Etoposide
1
Esomeprazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Drug-Related Side Effects and Adverse Reactions
×
Antineoplastic Agents
×
Clear all
NCT03882580
2023-04-24
NEOCARDIO
Groupe Hospitalier Pitie-Salpetriere
Unknown
5,000 enrolled